Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.
According to a new study, patients with diabetes become less adherent to their diabetes medication regimen following a diagnosis of cancer.
In treatment for metastatic breast cancer, eribulin is effective as a first-, second-, or third-line chemotherapy regimen.
How should a fibrin overgrowth on an internal catheter be managed when there is no blood return from the implanted port?
A drug used to treat Lou Gehrig's disease has also been found to improve the effectiveness of radiation therapy when administered to laboratory models with melanoma that metastasized to the brain.
Researchers have uncovered how melanoma becomes resistant to a promising new drug combination utilizing BRAF+MEK inhibitors after an initial period of tumor shrinkage.
Effectiveness of nanoparticle drugs was hindered by tumor microenvironment in triple-negative breast cancerJanuary 29, 2015
Nanoparticle drugs were considered to be a potential silver bullet against cancer, but they have not produced the anticipated improvement in overall survival rates.
Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.
Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.
The current classification system for colorectal cancer, based on genetic profiles, cannot be used to predict drug responses to FOLFIRI.
What are the treatment options for recurrent metastatic HER2-positive breast cancer after trastuzumab therapy?
A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.
A new use for an old drug shrinks a particular type of pancreatic cancer and stops it from spreading, according to new research.
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.
A gel containing the drug tamoxifen and applied to the skin was as effective as the pill form in reducing the growth of breast cancer cells in women with noninvasive cancer.
The addition of MM-398, a novel nanoliposome formulation of irinotecan, to standard treatment improves survival for metastatic pancreatic cancer patients who have already received gemcitabine.
A new combination of medications for treatment of recurrent ovarian cancer showed improved response rates, increased the rate of tumor shrinkage, and prolonged the time until cancers recurred
Nanomedicine technologies were utilized to develop a drug-delivery system that precisely targets and attacks cancer cells in the bone. It also increases bone strength and volume to prevent bone cancer progression.
A high-risk group of patients with follicular lymphoma could benefit from a novel drug combination, according to a new study published in the Journal of Experimental Medicine.
Five drug companies, the government, private foundations, and advocacy groups have come together to try a bold new way for testing cancer drugs. Described as a medical version of speed dating, physicians will sort through multiple experimental drugs and match patients to the one most likely to succeed.
Many older breast cancer patients with localized disease are taking drug treatments to prevent their cancer from returning, a new study finds. The research, covering a 7-year period, included more than 1,000 women, age 65 to 91 years, across the United States who had estrogen-positive breast cancer that had not spread.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.
Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.
The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.
In women with breast cancer, loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of a protein called PI3K-alpha.
The quest to improve survival of children with a high-risk brain tumor has led investigators to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers.
A new drug, ceritinib, appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
A patient with advanced bladder cancer experienced a complete response to the drug combination everolimus and pazopanib in a phase 1 clinical trial. Genomic profiling revealed information that could help identify other patients who may respond to everolimus and pazopanib.
- Women educated on overdiagnsosis are less likely to want mammogram
- New treatment method shrinks ovarian cancer tumors and improves chemotherapy effectiveness
- Epigenetic signatures differentiate triple negative breast cancers
- Novel drug approved for multiple myeloma
- New mechanism of acquired resistance to breast cancer drugs discovered
- Patients with detectable PSA after prostatectomy should receive more aggressive radiation therapy
- Increase in brain tumors is not attributed to mobile phone use
- Black men have lower preference for investigation of prostate cancer
- ASCO: Active surveillance for prostate cancer may decrease survival odds for some
- Finding a qualified acupuncture practitioner
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|